STAT+: Pharmalittle: We’re Reading About Warnings over Trump’s MFN Plan, Purdue Pharma Sentencing, and More

Why It Matters

The MFN scheme could force pharma firms to delay or forego launches, shrinking pipelines and limiting patient access worldwide, while reshaping pricing dynamics across major markets.

Key Takeaways

• Novartis CEO warns MFN policy threatens drug innovation pipeline
• MFN ties US Medicare prices to 19 reference countries
• Japan risks losing access to new blockbuster treatments
• Manufacturers may skip Japan launches to protect US pricing
• Delayed launches could limit patient access worldwide

Pulse Analysis

The Trump administration’s most‑favored‑nation (MFN) pricing framework links the price of drugs purchased through Medicare and Medicaid to the average price in a basket of 19 affluent nations. By anchoring U.S. prices to those set in Europe, Australia, South Korea and Japan, the policy aims to curb what officials call excessive American drug costs. However, the approach also reduces the price premium that U.S. markets traditionally provide, a key revenue source that funds research and development for high‑cost, innovative therapies.

Novartis chief executive Vas Narasimhan’s recent warning underscores the strategic dilemma facing multinational pharma firms. If the MFN rule forces lower U.S. prices, companies may postpone or cancel launches of novel medicines, especially those targeting small patient populations where profitability hinges on premium pricing. Japan, listed as a reference country, could see manufacturers deliberately avoid its market to prevent a downward price spill‑over into the United States, jeopardizing access to next‑generation blockbusters for Japanese patients.

The broader industry impact could be a slowdown in global drug pipelines, as reduced U.S. returns diminish the financial incentive to invest in breakthrough research. Companies might lobby for exemptions, seek alternative pricing models, or accelerate negotiations with foreign regulators to decouple U.S. pricing from reference‑country averages. Policymakers will need to balance cost‑containment goals with preserving the innovation ecosystem that underpins long‑term health outcomes worldwide.